A phase II trial combining estramustine, docetaxel and thalidomide in patients with androgen-independent metastatic prostate cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Docetaxel; Estramustine; Thalidomide
- Indications Prostate cancer
- Focus Therapeutic Use
- 15 Mar 2012 Biomarkers information updated
- 14 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 14 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.